scispace - formally typeset
P

Praveen Vikas

Researcher at University of Iowa

Publications -  26
Citations -  2382

Praveen Vikas is an academic researcher from University of Iowa. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 9, co-authored 20 publications receiving 1174 citations. Previous affiliations of Praveen Vikas include Roy J. and Lucille A. Carver College of Medicine & University of Iowa Hospitals and Clinics.

Papers
More filters
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

TL;DR: In this article, the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICP) was discussed. But, the authors did not provide guidance on recommended management.
Journal Article

Challenges of Rural Cancer Care in the United States

TL;DR: Given the projected increase in demand for cancer care due to the aging population and increasing number of Americans with health insurance through the Affordable Care Act, expansion of these efforts and development of new approaches are critical to ensure access to high-quality care.
Journal ArticleDOI

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.

TL;DR: The promise of combinatorial PARP inhibition and immunotherapy to improve patient outcomes in solid tumors is focused on, summarizing both early results and looking toward ongoing trials.
Journal ArticleDOI

The clinical promise of immunotherapy in triple-negative breast cancer.

TL;DR: The rationale for immunotherapy in TNBC is focused on, preclinical data, results from early clinical trials, and to summarize some ongoing trials are explored, which show the high number of stromal TILs is predictive of more favorable survival outcomes and response to chemotherapy.